A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

Pleiotropic Effects of Secretin: A Potential Drug Candidate in the Treatment of Obesity?




TekijätLaurila Sanna, Rebelos Eleni, Honka Miikka-Juhani, Nuutila Pirjo

KustantajaFrontiers in Endocrinology

Julkaisuvuosi2021

JournalFrontiers in Endocrinology

Lehden akronyymiFront. Endocrinol.

Vuosikerta12

DOIhttps://doi.org/10.3389/fendo.2021.737686

Verkko-osoitehttps://www.frontiersin.org/article/10.3389/fendo.2021.737686

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/67265386


Tiivistelmä

Secretin is the first hormone that has been discovered, inaugurating the era and the field of endocrinology. Despite the initial focus, the interest in its actions faded away over the decades. However, there is mounting evidence regarding the pleiotropic beneficial effects of secretin on whole-body homeostasis. In this review, we discuss the evidence from preclinical and clinical studies based on which secretin may have a role in the treatment of obesity.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 22:05